SEPTERNA INC

Third Rock Ventures’ new Septerna stake at near‑market prices signals long‑term confidence in its GPCR pipeline and upcoming clinical milestones.

RA Capital sells 746,500 shares of Septerna, a routine portfolio rebalancing, while the company’s oral GPCR pipeline (PTH1R & MRGPRX2) advances toward Phase 2 and fast‑track FDA reviews. Insights on pricing, insider buying, and future catalysts guid…

Insightful insider moves reveal Septerna Inc.’s confidence in its clinical‑trial wins and rising stock, offering investors a clear signal of growth potential.

Insider buying by Septerna’s Senior VP signals strong confidence in its Phase II GPCR pain drug, SEP‑101, and a bullish outlook for the biotech’s rising share price.

Insightful insider buying at Septerna Inc. shows long‑term confidence: low‑cost option exercise, strategic sales, and a bullish net purchase of 333 shares. Discover why investors should watch this biotech’s pipeline.

Daniel Long’s insider trades reveal a mix of strategic buying and high‑price selling, signaling confidence in Septerna’s drug‑discovery pipeline and hinting at possible upcoming liquidity events.